Clinical and immunological course of 17 patients who presented with arthralgia and autoimmune abnormalities under AI therapy.
| Patient | Age, Yrs | Clinical Course of Arthralgia | Autoantibodies under AI Therapy | Autoantibodies after Cessation |
|---|---|---|---|---|
| 1 | 69 | Resolution | ANA 1/320, RF 72 IU/ml | ANA 1/320, RF 60 IU/ml |
| 2 | 75 | No clinical improvement | ANA 1/320 | ANA 1/640 |
| 3 | 58 | Resolution | ANA 1/320, RF 244 IU/ml | ANA 1/160, RF 84 IU/ml |
| 4 | 72 | Resolution | ANA 1/320, ATGA 220 IU/ml | ANA 1/160, ATGA 240 IU/ml |
| 5 | 53 | Resolution, sicca syndrome | ANA 1/640, ATGA 335 IU/ml | ANA 1/2500, ATGA 290 IU/ml |
| 6 | 58 | Resolution | ANA 1/160, ATGA 320 IU/ml | ANA 1/160, ATGA 315 IU/ml |
| 7 | 71 | No clinical improvement, sicca syndrome | ANA 1/320, ACA | ANA 1/320, ACA |
| 8 | 61 | Resolution | RF 80 IU/ml | RF 5 IU/ml |
| 9 | 55 | 70% improvement | ANA 1/320 | ANA 1/160 |
| 10 | 60 | No clinical improvement | ANA 1/320, RF 44 IU/ml | ANA 1/320, RF 0 IU/ml |
| 11 | 62 | Resolution | ANA 1/160, ATGA 257 IU/ml | ANA 1/160, ATGA 255 IU/ml |
| 12 | 71 | Resolution | ANA 1/2500 | ANA 1/640 |
| 13 | 59 | Resolution | ANA 1/320 | ANA 1/160 |
| 14 | 56 | Resolution | ANA 1/320, RF 77 IU/ml | ANA 1/640, RF 8 IU/ml |
| 15 | 62 | 80% improvement | ANA 1/160, RF 132 IU/ml | ANA 1/160, RF 0 IU/ml |
| 16 | 71 | No clinical improvement, sicca syndrome | ANA 1/640, anti-SSA AB 58 | ANA 1/160, anti-SSA AB 30 |
| 17 | 56 | No clinical improvement | RF 38 IU/ml | RF 0 IU/ml |
AI: aromatase inhibitor; ANA: antinuclear antibodies; RF: rheumatoid factor; ATGA: antithyroglobulin antibodies; ACA: anticentromere antibodies.